TY  - JOUR
AU  - Reck, Martin
AU  - Garon, Edward B
AU  - Paz-Ares, Luis
AU  - Ponce, Santiago
AU  - Jaime, Jesus Corral
AU  - Juan, Oscar
AU  - Nadal, Ernest
AU  - Kiura, Katsuyuki
AU  - Widau, Ryan C
AU  - He, Shuang
AU  - Dalal, Rita
AU  - Lee, Pablo
AU  - Nakagawa, Kazuhiko
PY  - 2017
DO  - 10.1016/j.cllc.2017.11.003
UR  - http://hdl.handle.net/10668/11986
T2  - Clinical lung cancer
AB  - Despite the likelihood of an initial response to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non-small-cell lung cancer (NSCLC) patients develop disease progression. Antiangiogenic agents in combination with...
LA  - en
KW  - Antiangiogenic
KW  - Epidermal growth factor receptor
KW  - First-line
KW  - NCT02411448
KW  - Vascular endothelial growth factor receptor
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiogenesis Inhibitors
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Double-Blind Method
KW  - ErbB Receptors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Mutation
KW  - Vascular Endothelial Growth Factor Receptor-2
TI  - Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
TY  - research article
VL  - 19
ER  -